The VP.S ENCORE®

When Cold Storage Isn’t Enough and Complexity Isn’t an Option

The VPS-ENCORE® is a portable, accessible, and easy-to-use hypothermic oxygenated perfusion system built to address the limitations of current preservation methods.

  • Provides an alternative to ice-filled coolers and expensive preservation technologies

  • Granted Breakthrough Device Designation by the FDA in 2021

  • Operates without blood or blood products, using FDA-approved perfusate and passive cooling

  • Preclinical data suggests up to 24 hours of successful preservation; clinical trials aim for 8 hours

  • Developed to address critical medical needs and support patients awaiting life-saving transplants

The Current Limits Meet a New Approach

Current Challenges

Challenge 1 Ice-filled coolers remain the standard, limiting preservation to 4–6 hours.

Challenge 2 Complex systems require blood, custom perfusate, and significant setup time.

Challenge 3 High system and cartridge costs limit accessibility.

Challenge 4 Time constraints contribute to loss of donor organs and missed transplant opportunities.

The VP.S ENCORE® Response

Response 1 Maintains controlled perfusion during transport, with a built-in cold storage fallback to protect the graft if circulation is interrupted—minimizing ischemic risk across longer distances.

Response 2 Built to streamline workflows using familiar, standardized materials and eliminating system components that delay or complicate setup.

Response 3 Engineered with cost-efficiency in mind—durable materials and a simplified system architecture help lower acquisition and operational costs without sacrificing performance.

Response 4 Gives recovery teams more control over timing and logistics—extending preservation windows while accommodating real-world transport constraints.

Built for the Demands of Transplant Care

Adaptable by Design

Built for versatility, the VP.S ENCORE® can be adapted to preserve a range of organs and vascularized tissues—supporting future applications in organ banking, xenotransplantation, and ex vivo therapies. This flexibility may help improve donor-recipient matching and reduce complications such as primary graft dysfunction.

Portable Without Compromise

Compact, built for single-person handling, and powered by a long-lasting battery, the VP.S ENCORE® delivers uninterrupted preservation without relying on specialized transport or additional staff.

Ease of Integration

Designed for seamless integration into existing clinical workflows, the VP.S ENCORE® requires no specialized fluids, infrastructure, or equipment—supporting faster adoption while maintaining standard transplant protocols.

Regulatory Note: VP.S ENCORE® is an investigational device, currently in development and not yet approved for commercial use by the FDA. Any features or descriptions shown are for informational purposes only.